Moleculin Biotech Inc (MBRX) Earnings Report, Financial Results, Financial analysis

Moleculin Biotech Inc increased first quarter of 2023 net loss per share of $-0.28 compare to net loss per share of $-0.24 recorded in the same quarter a year ago a decrease compare to $-0.24 realized in previous quarter.

*first quarter of 2023*
Earnings Per Share	Revenues
$ -0.28	$ 0 Mill
$-0.04	Unch.

Moleculin Biotech Inc 's Revenue fell by 0 % in first quarter of 2023 (Mar 31 2023) year on year, to $0 million and declined by sequentially.

Moleculin Biotech Inc is Expected to report next financial results on August 11, 2023.

More on MBRX's Income Statement

MBRX's NET INCOME

Moleculin Biotech Inc 's in thefirst quarter of 2023 recorded net loss of $-7.915 million, an increase from net loss of $-6.867 million in I. Quarter a year ago.

Sequentially net loss advanced

More on MBRX's Growth

Moleculin Biotech Inc Inventories
In Mar 31 2023 company's net cash and cash equivalents decreased by $-6 million

Earnings quality

Moleculin Biotech Inc does not pay out common stock dividend.

In trailing twelve-month period Moleculin Biotech Inc payed $ -1.00 cash per share, on a free-cash flow basis .

Book value fell by -12.67 % sequentially to $1.59 per share, -21.84% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 1.20 per share from $ 1.43.

Company issued 0.07 million shares or 0.23 % in Mar 31 2023.

• More on MBRX's Dividends

Market Capitalization (Millions)	18
Shares Outstanding (Millions)	29
Total Debt (Millions $)	-
Revenue (TTM) (Millions $)	-
Net Income (TTM) (Millions $)	-30
Cash Flow (TTM) (Millions $)	-29
Capital Exp. (TTM) (Millions $)	0
Dividend TTM ($)	0 $
Dividend Yield TTM (%)	-
Employees (TTM) $	-

Earnings quality

Moleculin Biotech Inc does not pay out common stock dividend.

In trailing twelve-month period Moleculin Biotech Inc had negative $ -1.00 cash flow per share, on a free-cash flow basis .

Book value fell by -12.67 % sequentially to $1.59 per share, -21.84% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 1.20 per share from $ 1.43.

Company issued 0.07 million shares or 0.23 % in Mar 31 2023.

• More on MBRX's Balance Sheets

Market Capitalization (Millions)	18
Shares Outstanding (Millions)	29
Total Debt (Millions $)	-
Revenue (TTM) (Millions $)	-
Net Income (TTM) (Millions $)	-30
Cash Flow (TTM) (Millions $)	-29
Capital Exp. (TTM) (Millions $)	0
Dividend TTM ($)	0 $
Dividend Yield TTM (%)	-
Employees (TTM) $	-

Moleculin Biotech Inc

MBRX's Financial Statements and Analysis